ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "histone acetylation and anti-CCP antibodies"

  • Abstract Number: 47 • 2019 ACR/ARP Annual Meeting

    Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity

    Peter Sahlström 1, Lisa Liljefors 1, Vijay Joshua 2, Natalia Sherina 1, Radha Thyagarajan 1, Lena Israelsson 2, Ragnhild Stålesen 2, Monika Hansson 3, Khaled Amara 2, Ulf Reimer 4, Leonid Padyukov 1, Elisabet Svenungsson 5, Karin Lundberg 1, Anca Catrina 3, Lars Klareskog 3, Vivianne Malmström 2 and Caroline Grönwall2, 1Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 3Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 4JPT Peptide Technologies, Berlin, Germany, 5Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Serum anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA) display reactivity to a variety of cit-autoantigens. Studies of human ACPA mAbs have revealed that…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology